Three Anavex Life Sciences directors resign, citing strategic disagreements

Anavex Life Sciences Corp. disclosed in an 8-K filing that Dr. Jiong Ma, Mr. Gautam Patel and Dr. Adrian Senderowicz resigned from the company's Board of Directors effective October 28, 2026.¹ Before stepping down, Dr. Ma had chaired the Board and served on its Audit Committee, Mr. Patel had served on the Audit Committee, and Dr. Senderowicz had not held any committee assignments.¹

Each departing director cited misalignment with the company's direction in resignation letters attached to the filing. According to the filing, Dr. Ma indicated her views on the company's strategic direction were not fully aligned with those of the Board and management.¹ Patel and Senderowicz offered similar explanations: both said their personal views on the company's strategy to execute its business plan did not sufficiently align with those of the Board and management.¹

Anavex noted that it gave each of the three directors an opportunity to respond to the company's description of events, and said it would file any such response as an amendment to the Form 8-K within two business days of receiving it.¹

Separately, the filing stated that on November 1, 2026, the Board approved a reconstitution of its three standing committees, naming Dr. Claus van der Velden as Audit Committee chair alongside Dr. Peter Donhauser and Dr. Axel Paeger, Dr. Donhauser as Compensation Committee chair with Dr. van der Velden, and Dr. Paeger as chair of the Nominating & Corporate Governance Committee with Dr. Donhauser.¹

The 8-K was signed by Sandra Boenisch, the company's Principal Financial Officer and Treasurer, and dated November 2, 2026.